Journal article
Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis.
Abstract
OBJECTIVES: To compare the impact of ankylosing spondylitis (AS) on health-related quality of life (HRQL) and of adalimumab on initial and sustained improvement in HRQL for patients with active AS versus the general US population.
METHODS: Data from the 5-year ATLAS trial were analysed. HRQL burden of AS and treatment impact on HRQL were assessed by comparing health status and utility scores from ATLAS (Short Form 36 Health Survey [SF-36] and …
Authors
Kimel M; Revicki D; Rao S; Fryback D; Feeny D; Harnam N; Thompson C; Cifaldi M
Journal
Clinical and Experimental Rheumatology, Vol. 29, No. 4, pp. 624–632
Publication Date
2011
ISSN
0392-856X
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdalimumabAdolescentAdultAgedAged, 80 and overAnti-Inflammatory AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCost of IllnessDisability EvaluationDouble-Blind MethodFemaleHealth StatusHealth Status IndicatorsHealth SurveysHumansMaleMiddle AgedQuality of LifeRecovery of FunctionSpondylitis, AnkylosingSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesYoung Adult